Postmarketing Drug Safety Compliance: 2019 Inspection Findings

Namita Kothary from CDER’s Division of Enforcement and Postmarketing Safety provides an overview of the Postmarketing Adverse Drug Experience (PADE) compliance program. She also discusses inspection findings and trends from PADE inspections completed in Fiscal Year 2019 (October 1, 2018 to September 30, 2019).
Learn more at https://www.fda.gov/drugs/postmarketi...
_______________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Visit https://www.fda.gov/cdersbia and www.fda.gov/cderbsbialearn for news and a repository of training activities.

Email: [email protected]
Phone: (301) 796-6707 I (866) 405-5367
LinkedIn:   / cder-small-business-and-industry-assistance  
Twitter:   / fda_drug_info  
CDER small business e-mail update subscription: https://updates.fda.gov/subscriptionm...